MEDP Medpace Holdings Earnings and EPS analysis

?
Relative Growth: Rel. Growth: 97
Relative Strength: Rel. Strength: 78
Relative Valuation: Rel. Valuation: 36
Relative Profitability: Rel. Profitability: 51

EPS in 2026 (TTM): $17.37

Last Report Period Date: Jun 30, 2026

As of July this year, based on Medpace Holdings's latest financial report, the company's current EPS (TTM) is $17.37. Medpace Holdings's earnings per share in 2025 came in at $15.64, marking an increase from $13.06 in 2024. Medpace Holdings's EPS for the quarterly period ending on Jun 30, 2026 was $4.31.

MEDP earnings history

Historical annual and quarterly earnings per share (EPS) data for Medpace Holdings
EPS (TTM)
$17.37
EPS Growth YoY (Quarterly)
36.4%
EPS (Quarterly)
$4.31
EPS Growth (Quarterly)
-0.9%

The yearly EPS in 2025 was $15.64, an increase of 19.8% compared to $13.06 recorded in 2024. The quarterly EPS for the period ending Jun 30, 2026, was $4.31, marking a 36.4% increase compared to the same quarter last year. MEDP's TTM EPS is $17.37 as of June 2026. Medpace Holdings's EPS for 2024 was $13.06, a 42% rise from 2023.

MEDP earnings chart

MEDP EPS growth history

Earnings per share growth rates over time
EPS Growth YoY (Quarterly)
36.4%
EPS growth YoY
19.8%
EPS growth 3Y avg
27.4%
EPS growth 5Y avg
30.9%

Medpace Holdings has recorded a growth in earnings per share of 36.4% over the past 12 months (YoY, quarterly). For the last three years, MEDP had an average yearly EPS growth of 27.4%. Medpace Holdings had an average annual EPS growth of 30.9% over the last five years.

MEDP Earnings Waterfall

Breakdown of revenue, profit and net income for Medpace Holdings

MEDP Earnings vs Peers

What are the earnings of MEDP compared to its peers
Stock name Price to Earnings EPS grwoth 1Y EPS grwoth 3Y EPS grwoth 5Y
ORMP Oramed Pharmaceuticals Inc 1.52 418.8% N/A N/A
OMER Omeros Corp 7.53 98.1% N/A N/A
MEDP Medpace Holdings Inc 34.62 19.8% 27.4% 30.9%
OLMA Olema Pharmaceuticals Inc N/A 15% N/A N/A
VIVS VivoSim Labs Inc. N/A -214.7% N/A N/A
ORIC Oric Pharmaceuticals Inc N/A 19.7% N/A N/A

All data is based on quarterly TTM periods, unless otherwise specified.